Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
Aim and Objective: To compare efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression.Materials and Methods: A total of 60 patients of depression were randomized into two groups after meeting inclusion criterion. In the first 3 weeks, escitalopram 10 mg/day was g...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Perspectives in Clinical Research |
| Subjects: | |
| Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2016;volume=7;issue=1;spage=45;epage=50;aulast=Gupta |
| _version_ | 1817968686646951936 |
|---|---|
| author | Brij Mohan Gupta Samir H Zargar Manu Arora Vishal R Tandon |
| author_facet | Brij Mohan Gupta Samir H Zargar Manu Arora Vishal R Tandon |
| author_sort | Brij Mohan Gupta |
| collection | DOAJ |
| description | Aim and Objective: To compare efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression.Materials and Methods: A total of 60 patients of depression were randomized into two groups after meeting inclusion criterion. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks in group 1 (n = 30). Desvenlafaxine in the first 3 weeks was given 50 mg/day and 100 mg/day for the next 3 weeks in group 2 (n = 30). The parameters evaluated during the study were efficacy assessments byHamilton Scale of Rating Depression (HAM-D), Hamilton Rating Scale of Anxiety (HAM-A), and Clinical Global Impression (CGI). Safety assessments were done by UKU-scale. Results: Escitalopram and desvenlafaxine significantly (P < 0.001), reduced HAM-D, HAM-A, and CGI scores from their respective base lines. However, on comparison failed show any statistical difference at 3 and 6 weeks of treatment. Escitalopram and desvenlafaxine were both found to be safe and well-tolerated and there was not much difference between the two groups as evident from UKU Scale and their effect on various biochemical parameters. Conclusion: The present study demonstrated similar efficacy and safety in reducing depression and anxiety with both escitalopram and desvenlafaxine, but clinical superiority of one drug over the other cannot be concluded due to limitations of the small sample size. |
| first_indexed | 2024-04-13T20:11:38Z |
| format | Article |
| id | doaj.art-2790684dbced4c4c811ab68089b59305 |
| institution | Directory Open Access Journal |
| issn | 2229-3485 |
| language | English |
| last_indexed | 2024-04-13T20:11:38Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Perspectives in Clinical Research |
| spelling | doaj.art-2790684dbced4c4c811ab68089b593052022-12-22T02:31:50ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852016-01-0171455010.4103/2229-3485.173771Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trialBrij Mohan GuptaSamir H ZargarManu AroraVishal R TandonAim and Objective: To compare efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression.Materials and Methods: A total of 60 patients of depression were randomized into two groups after meeting inclusion criterion. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks in group 1 (n = 30). Desvenlafaxine in the first 3 weeks was given 50 mg/day and 100 mg/day for the next 3 weeks in group 2 (n = 30). The parameters evaluated during the study were efficacy assessments byHamilton Scale of Rating Depression (HAM-D), Hamilton Rating Scale of Anxiety (HAM-A), and Clinical Global Impression (CGI). Safety assessments were done by UKU-scale. Results: Escitalopram and desvenlafaxine significantly (P < 0.001), reduced HAM-D, HAM-A, and CGI scores from their respective base lines. However, on comparison failed show any statistical difference at 3 and 6 weeks of treatment. Escitalopram and desvenlafaxine were both found to be safe and well-tolerated and there was not much difference between the two groups as evident from UKU Scale and their effect on various biochemical parameters. Conclusion: The present study demonstrated similar efficacy and safety in reducing depression and anxiety with both escitalopram and desvenlafaxine, but clinical superiority of one drug over the other cannot be concluded due to limitations of the small sample size.http://www.picronline.org/article.asp?issn=2229-3485;year=2016;volume=7;issue=1;spage=45;epage=50;aulast=GuptaComparative effectiveness research, observational studies, randomized controlled trials |
| spellingShingle | Brij Mohan Gupta Samir H Zargar Manu Arora Vishal R Tandon Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial Perspectives in Clinical Research Comparative effectiveness research, observational studies, randomized controlled trials |
| title | Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial |
| title_full | Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial |
| title_fullStr | Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial |
| title_full_unstemmed | Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial |
| title_short | Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial |
| title_sort | efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression a preliminary 1 year prospective randomized open label comparative trial |
| topic | Comparative effectiveness research, observational studies, randomized controlled trials |
| url | http://www.picronline.org/article.asp?issn=2229-3485;year=2016;volume=7;issue=1;spage=45;epage=50;aulast=Gupta |
| work_keys_str_mv | AT brijmohangupta efficacyandsafetyofescitalopramversusdesvenlafaxineinthetreatmentofmajordepressionapreliminary1yearprospectiverandomizedopenlabelcomparativetrial AT samirhzargar efficacyandsafetyofescitalopramversusdesvenlafaxineinthetreatmentofmajordepressionapreliminary1yearprospectiverandomizedopenlabelcomparativetrial AT manuarora efficacyandsafetyofescitalopramversusdesvenlafaxineinthetreatmentofmajordepressionapreliminary1yearprospectiverandomizedopenlabelcomparativetrial AT vishalrtandon efficacyandsafetyofescitalopramversusdesvenlafaxineinthetreatmentofmajordepressionapreliminary1yearprospectiverandomizedopenlabelcomparativetrial |